Scottish Medicines Consortium cabozantinib (Cabometyx)
in the absence of a submission from the holder of the marketing authorisation:
cabozantinib (Cabometyx) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.